Genmab's leukaemia drug hope delivers promising results  

2008.12.10
Genmab and GlaxoSmithKline have announced that ofatumumab has shown promising results in patients with chronic lymphocytic leukaemia who are refractory to conventional therapy
Danish-American biotech company Genmab and US pharma giant GlaxoSmithKline (GSK) have announced that its investigational drug ofatumumab has shown promising results in patients with chronic lymphocytic leukaemia (CLL) who are non-responsive or ineligible for currently available treatments, writes the company in a press release.
 
Lead investigator Professor Anders Österborg of Karolinska Hospital in Sweden says: "There is a great unmet medical need among patients with CLL that is refractory to conventional therapy. The clinical responses and the tolerability profile we are seeing with ofatumumab in this group of CLL patients are very encouraging."
 
Ofatumumab has not yet been approved for any indication in any market. But Genmab's CEO Lisa N. Drakeman comments in the press release: "We are working together with GSK to bring this urgently needed new medicine to market as quickly as possible, and are currently collaborating on filing submissions."
 
Genmab and GSK plan to file a Biologics License Application with the FDA in January 2009. CLL is the most common leukaemia and one of the most common malignant lymphoid diseases in the Western world. Globally, leukaemia accounts for some 300,000 new cases and 222,000 deaths.
 
Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has a portfolio of products in development to treat cancer, rheumatoid arthritis, infectious diseases and other inflammatory conditions. Genmab is listed on the OMX Nordic Exchange Copenhagen.
 
Link > Genmab                    

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×